We then selected the cervical cancer cell line C33A, which is mutated for both PIK3CA and PTEN (PIK3CA R88Q, PTEN R233*) and expresses high levels of p-AKT at baseline, to assess the response to two allosteric AKT inhibitors, SC-66 and MK-2206. The gene discussed is PTEN; the disease is cervical carcinoma.